Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Scientia Pharmaceutica|February 4, 2016
A Rapid, Cost-Effective Pre-Clinical Method to Screen for Pro- or Antiarrhythmic Effects of Substances in an Isolated Heart PreparationJohn Joseph Borg
Pharmacological Research|July 4, 2021
Aducanumab for Alzheimer's disease: A regulatory perspectiveRobert Nisticò, John Joseph Borg
Drug Safety|February 22, 2011
Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilanceJohn-Joseph Borg, George Aislaitner, Michal Pirozynski, et al.
Expert Opinion on Drug Safety|October 13, 2016
A review of the National pharmacovigilance system in Malta - implementing and operating a pharmacovigilance management systemAmy Tanti, Benjamin Micallef, Anthony Serracino-Inglott, et al.
The International Journal of Risk & Safety in Medicine|February 28, 2013
Medication errors through a national pharmacovigilance database approach: a study for MaltaAmy Tanti, Miriam Camilleri, Patricia Vella Bonanno, et al.
Scientia Pharmaceutica|April 9, 2015
Reflections on Decisions Made on the Well-Established Use of Medicinal Products by EU Regulators and the ECJJohn Joseph Borg, Andrea Laslop, Luca Pani, et al.
Frontiers in Pharmacology|June 19, 2023
Alzheimer's disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy?Daniela Melchiorri, Sara Merlo, Benjamin Micallef, et al.
European Journal of Ophthalmology|June 20, 2020
Treatment of Leber's hereditary optic neuropathy: An overview of recent developmentsMarta Zuccarelli, Janis Vella-Szijj, Anthony Serracino-Inglott, et al.
Expert Opinion on Drug Safety|October 15, 2021
Improving the data quality of spontaneous ADR reports: a practical example from MaltaMarta Zuccarelli, Benjamin Micallef, Dianne Butler, et al.
Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society|March 28, 2017
Changing paradigms in bioequivalence trials submitted to the EMA for evaluation - A clinical and regulatory perspectiveNathaniel Refalo, Daniel Chetcuti, Amy Tanti, et al.
Pageof 3